Shenzhen Kangtai Biological Products Co., Ltd. (SHE: 300601) today announced the signing of a technology‑transfer agreement with Professor Zou Quanming’s team at Army Medical University. Kangtai will acquire the team’s original Klebsiella pneumoniae pneumonia vaccine for a conversion fee of 530 million yuan. Payment will be milestone‑based, with the first tranche due upon the achievement of predefined development milestones.
Deal Highlights
| Element | Detail |
|---|---|
| Acquirer | Shenzhen Kangtai Biological Products |
| Technology Owner | Professor Zou Quanming, Army Medical University |
| Asset | Original Klebsiella pneumoniae pneumonia vaccine |
| Purchase Price | 530 million yuan (≈ $78 million) |
| Payment Terms | Milestone‑driven, with payments tied to development progress |
Vaccine Profile
- Target Pathogen – Klebsiella pneumoniae, a leading cause of drug‑resistant pneumonia.
- Efficacy – > 80 % protective efficacy in pre‑clinical pneumonia models against a broad panel of clinical strains.
- Patents – 9 national invention patents secured; clinical‑trial dossier to be filed immediately.
- Market Need – No approved vaccine exists domestically or internationally, underscoring the potential commercial value.
Strategic Context
- China’s Antimicrobial Innovation Drive – The acquisition aligns with national priorities to strengthen domestic vaccine development against super‑drug‑resistant bacteria.
- Milestone‑Based Funding – Enables Kangtai to align investment with tangible progress, mitigating risk while accelerating clinical development.
- Potential for Global Expansion – Success could open pathways to international licensing and collaboration with multinational partners.
Forward‑Looking Statements
This release contains forward‑looking statements that involve risks and uncertainties. Actual results may differ materially.-Fineline Info & Tech
